Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Anaveon has raised €136M across 2 funding rounds from 7 investors, most recently a Series B round in Dec 2021. Based in Zurich, Switzerland; founded 2017; active in Healthtech. Data as of 6 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2021-12-16 | Series B | €105M | Cowen Healthcare Investments,Forbion Capital Partners,Novartis Venture Fund,Pfizer Ventures,Pontifax,Syncona Partners | View deal → |
| 2019-01-01 | Series A | €31M | Syncona Partners LLP | View deal → |
